Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Short-term Thiazolidinedione Treatment on Vascular Risk Markers in Type 2 Diabetes
NCT00571506Phase 4Completed
- Sponsor
- University of Arkansas
- Start
- May 2004
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Rosiglitazone with Pioglitazone (2 arms). Primary endpoint: Spontaneous and agonist-induced platelet aggregation at 3 months. Started May 2004; status: completed.
02
Drugs
rosiglitazonepioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00571506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571506.